I-Mab Files 6-K, Incorporates Exhibit 99.1

Ticker: NBP · Form: 6-K · Filed: Aug 11, 2025 · CIK: 1778016

Sentiment: neutral

Topics: filing-update, registration-statement

TL;DR

I-Mab filed a 6-K to link new info into its F-3. No new financials, just an update.

AI Summary

I-Mab, a biopharmaceutical company, filed a Form 6-K on August 11, 2025, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on Form F-3 (File No. 333-286954). This filing does not contain new financial information but serves to update or supplement previously filed documents.

Why It Matters

This filing indicates I-Mab is updating its public disclosures, potentially related to ongoing or future capital-raising activities or other corporate events, by referencing an exhibit within its existing F-3 registration statements.

Risk Assessment

Risk Level: low — This is a routine filing to incorporate documents by reference, not a disclosure of new material financial events or risks.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing by I-Mab?

The purpose of this Form 6-K is to incorporate by reference Exhibit 99.1 into I-Mab's Registration Statements on Form F-3 (File No. 333-286954).

What is Exhibit 99.1?

The filing does not specify the content of Exhibit 99.1, only that it is being incorporated by reference.

When was this Form 6-K filed?

This Form 6-K was filed on August 11, 2025.

Does this filing contain new financial results for I-Mab?

No, this filing is for the purpose of incorporation by reference and does not appear to contain new financial results.

What type of company is I-Mab?

I-Mab is identified as a biopharmaceutical company ('PHARMACEUTICAL PREPARATIONS [2834]').

Filing Stats: 246 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2025-08-11 07:06:07

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. I-MAB By : /s/ Joseph Skelton Name : Joseph Skelton Title : Chief Financial Officer Date: August 11, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing